Tuesday, September 13, 2016 8:50:28 AM
Source: Business Wire
AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. A safety committee reviewed the trial data and concluded AB-SA01 was well-tolerated by subjects in the trial and there were no drug-related serious adverse events.
The trial was conducted under a Collaborative Research and Development Agreement with the U.S. Army at the Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center in Silver Spring, Maryland. AmpliPhi expects the complete study report will be finalized before the end of 2016.
“Announcing topline results for the first U.S.-based trial of AB-SA01 is a significant and necessary step towards unlocking the commercial potential of phage therapy to combat antibiotic-resistant bacteria,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “We thank our collaborators at WRAIR, and look forward to announcing the complete data from this trial, as well as final data from our Phase 1 trial of AB-SA01 in patients with chronic rhinosinusitis, later this year.”
The double-blind, placebo-controlled study was designed to evaluate the safety of AB-SA01 administered topically to the skin of 12 healthy adult volunteers between the ages of 18 and 60. Volunteers were split into two cohorts of six participants each, and received either the low-dose (1 x 108 PFU/mL) or high-dose (1 x 109 PFU/mL) of AB-SA01, administered topically to the forearm under an occlusive bandage. Placebo was similarly administered to the volunteer’s opposite forearm, allowing each participant to serve as his or her own control. Participants received AB-SA01 and placebo daily for three consecutive days and were monitored following treatment.
Despite vigorous eradication efforts, S. aureus is one of the most common causes of hospital-acquired infections. It can cause pneumonia, infect prosthetic joints, skin and other soft tissues and is a leading cause of bloodstream infections – typically as a consequence of traumatic injury, surgery or use of catheters or injectable drugs – where it can go on to infect and damage the heart, joints and bones.
For more information, visit www.ampliphibio.com.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (NYSEMKT:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is currently conducting a Phase 1 clinical trial of AB-SA01 for the treatment of S. aureus in chronic rhinosinusitis patients and another Phase 1 clinical trial to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi expects to report final data for both trials by the end of 2016. AmpliPhi is also developing bacteriophage therapeutics targeting Pseudomonas aeruginosa and Clostridium difficile in collaboration with a number of leading organizations focused on the advancement of bacteriophage-based therapies.
About Bacteriophage
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
Recent ARMP News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:35:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:03:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/23/2024 09:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:27 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/15/2023 10:24:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2023 11:17:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:15:29 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/03/2023 08:35:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/03/2023 08:34:24 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/24/2023 08:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 08:30:30 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 07/11/2023 12:27:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:15:48 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM